The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
25 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $23,213,527 in first-year total cost, median $763,225.
Most frequent study sections
- Drug Discovery and Molecular Pharmacology B Study Section[DMPB]14
- Drug Discovery for the Nervous System Study Section[DDNS]3
- Chemical Biology and Probes Study Section[CBP]2
- Chronic Dysfunction and Integrative Neurodegeneration Study Section[CDIN]2
- Molecular and Cellular Neuropharmacology Study Section [MCNP]1
Most frequent institutions
- SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE4
- JOHNS HOPKINS UNIVERSITY2
- OREGON HEALTH & SCIENCE UNIVERSITY2
- WEILL MEDICAL COLL OF CORNELL UNIV2
- BROAD INSTITUTE, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Discovery of GPR52 ligand probes for cocaine use disorder1R01DA060228-01A1 | ALLEN, JOHN AZHOU, JIA | UNIVERSITY OF TEXAS MED BR GALVESTON, TX | $795,090 | DMPB |
| 2025 | siRNA-mediated Knockdown of INPP5D to Modulate Microglia Activity for the Treatment of Alzheimer's Disease1R01AG093015-01 | OBLAK, ADRIAN LYNNRICHARDSON, TIMOTHY I | INDIANA UNIVERSITY INDIANAPOLIS, IN | $792,074 | DMPB |
| 2025 | Chemokine Receptor Antagonists (CRAs): Characterization in Preclinical Models of Methamphetamine Use Disorder1R01DA061116-01A1 | RAWLS, SCOTT M. | TEMPLE UNIV OF THE COMMONWEALTH, PA | $552,629 | DMPB |
| 2024 | Fragment-based discovery of STEP modulators in Alzheimer's disease1RF1AG087011-01 | COSFORD, NICHOLAS DAVIDTAUTZ, LUTZ | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, CA | $2,835,382 | DMPB |
| 2024 | Small molecule inhibitors of CAPON-induced tau aggregation1RF1AG084635-01A1 | GABR, MOUSTAFA | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $1,980,378 | DMPB |
| 2024 | Intranasal delivery of VGF-derived peptides in a preclinical model of Alzheimer's disease1R01AG084699-01 | EHRLICH, MICHELLE ESALTON, STEPHEN R | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $844,721 | CDIN |
| 2024 | New epigenetic inhibitors for Alzheimer's disease treatment1R01AG086433-01 | WANG, CHANGNINGZHANG, CAN MARTIN | MASSACHUSETTS GENERAL HOSPITAL, MA | $806,956 | DMPB |
| 2024 | Discovery of first-in-class small molecule TREM2 ligands as therapeutics for Alzheimer's disease1R01AG083512-01A1 | GABR, MOUSTAFA | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $768,267 | DMPB |
| 2024 | Discovery and optimization of ApoE4 correctors for the treatment of Alzheimer's Disease1R01AG086914-01 | JACKSON, MICHAEL | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, CA | $730,480 | CBP |
| 2024 | Identification and characterization of chemical probes of TRIO GEF1 activity1R01MH132685-01A1 | KOLESKE, ANTHONY J | YALE UNIVERSITY, CT | $573,147 | CBP |
| 2024 | Microglia-targeted glutaminase inhibition forthe treatment of chronic stress-associated depression1R56MH135895-01 | ZHU, XIAOLEI | JOHNS HOPKINS UNIVERSITY, MD | $526,191 | DMPB |
| 2024 | A Novel Method to Enhance Drug Delivery to the Brain1R01AG082273-01A1 | KUCZERA, KRZYSZTOFSIAHAAN, TERUNA J.ZHAO, LIQIN | UNIVERSITY OF KANSAS LAWRENCE, KS | $487,741 | ZRG1 |
| 2024 | Efficacy, safety, and mechanisms of brain penetrable erythropoietin in Alzheimer’s disease mouse models1R01AG085724-01 | SUMBRIA, RACHITA | CHAPMAN UNIVERSITY, CA | $342,000 | ZRG1 |
| 2024 | Antisense Oligonucleotides for Progranulin-deficient Frontotemporal Dementia2R56AG064069-06 | NGUYEN, ANDREW D. | SAINT LOUIS UNIVERSITY, MO | $75,350 | DMPB |
| 2023 | Exercise Mimetics for Dementia and Alzheimer's Disease1RF1AG077160-01A1 | BURRIS, THOMAS PELGENDY, BAHAA | UNIVERSITY OF FLORIDA, FL | $2,262,938 | DDNS |
| 2023 | GPR39 as a Therapeutic Target in Aging-Related Vascular Cognitive Impairment and Dementia1RF1AG079890-01A1 | ALKAYED, NABIL J | OREGON HEALTH & SCIENCE UNIVERSITY, OR | $2,244,471 | DMPB |
| 2023 | Discovery and development of apoE4 correctors for the treatment of Alzheimer's disease1R56AG080525-01A1 | HYMAN, BRADLEY T.JACKSON, MICHAEL | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, CA | $919,106 | DMPB |
| 2023 | Discovery and development of GPR3 agonists for nicotine cessation1R01DA058493-01A1 | FOWLER, CHRISTIE DGAY, ELAINE ARRINGTON | RESEARCH TRIANGLE INSTITUTE, NC | $878,861 | MCNP |
| 2023 | Optimization of Drug-like Properties of CRFBP-CRF2 Negative Allosteric Modulators for Alcohol Use Disorder1R01AA030888-01A1 | SHEFFLER, DOUGLAS J | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, CA | $851,142 | DMPB |
| 2023 | Discovery of allosteric activators of phospholipase C-gamma2 to treat Alzheimer's disease1R56AG083424-01 | PEARCE, KENNETH HUGHSONDEK, JOHN EZHANG, QISHENG | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $763,225 | DMPB |
| 2023 | CD98hc Brain Shuttles for Delivering Off-the-shelf Neuroprotective Antibodies in Alzheimer's Disease1R01AG080016-01 | GREINEDER, COLIN FREDTESSIER, PETER M | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $721,526 | ZRG1 |
| 2023 | Development of neutral sphingomyelinase 2 (nSMase2) inhibitors for the treatment of Alzheimer's disease1R01AG084728-01 | RAIS, RANASLUSHER, BARBARA STAUCHTSUKAMOTO, TAKASHI | JOHNS HOPKINS UNIVERSITY, MD | $651,180 | DMPB |
| 2023 | Development of soluble epoxide hydrolase inhibitors for the treatment of Alzheimer's disease1R01AG080186-01 | LEE, KIN SING STEPHEN | MICHIGAN STATE UNIVERSITY, MI | $649,899 | DDNS |
| 2023 | Evaluating a novel, orally-active TREM2-targeting drug in AD1R01AG079949-01A1 | GRAY, NORA | OREGON HEALTH & SCIENCE UNIVERSITY, OR | $443,793 | CDIN |
| 2022 | Potentiate Cav3.3 To Treat Cognitive Deficits Associated with Impaired Sleep Spindle1R01MH131719-01 | PAN, JEN QIANWEÏWER, MICHEL | BROAD INSTITUTE, INC., MA | $716,980 | DDNS |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.